Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 189

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA 1c without causing weight gain or increased hypoglycaemia

Rosenstock, J., Rendell, M. S., Gross, J. L., Fleck, P. R., Wilson, C. A., Mekki, Q. · 2009 · Diabetes, Obesity and Metabolism

Abstract

Aims : To assess the efficacy and safety of alogliptin added to insulin in patients with type 2 diabetes inadequately controlled with insulin alone or combined with metformin. Methods : In this 26‐week, double‐blind, placebo‐controlled study, 390 patients were randomized to receive alogliptin 12.5 mg (n = 131), alogliptin 25 mg (n = 129) or placebo (n = 130) once daily, as add‐on to stable insulin therapy with or without metformin. The primary endpoint was change in haemoglobin A 1C (HbA 1C ) at week 26. Results : At week 26, mean HbA 1C changes from the mean baseline value of 9.3% were significantly greater for alogliptin 12.5 mg (–0.63 ± 0.08%) and alogliptin 25 mg (−0.71 ± 0.08%) than placebo (−0.13 ± 0.08%; p < 0.001). Significantly greater proportions of patients receiving alogliptin 12.5 or 25 mg than placebo had HbA 1C decreases of ≥0.5, ≥1.0 and ≥1.5%. Insulin doses remained unchanged, and there were no differences in the proportions of patients experiencing hypoglycaemia among placebo (24%), alogliptin 12.5 mg (27%) and alogliptin 25 mg (27%). Mean weight increases from baseline at week 26 were similar for placebo (0.6 ± 0.2 kg), alogliptin 12.5 mg (0.7 ± 0.2 kg) and alogliptin 25 mg (0.6 ± 0.2 kg). Incidences of overall adverse events, and of gastrointestinal, dermatological and infection‐related events, were similar among groups. Conclusions : Adding alogliptin to previous insulin therapy (with or without metformin) significantly improved glycaemic control in patients with type 2 diabetes inadequately controlled on insulin, without causing weight gain or increasing the incidence of hypoglycaemia. Further studies are warranted to explore the role of alogliptin added to optimized basal insulin regimens.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1463-1326.2009.01124.x

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 189

Metadata

Authors
Rosenstock, J., Rendell, M. S., Gross, J. L., Fleck, P. R., Wilson, C. A., & Mekki, Q.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2009-11-10
Volume
11
Issue
12
Pages
1145-1152
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2059245135
Cited by
189
References
2
FWCI
10.44
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA 1c without causing weight gain or increased hypoglycaemia. https://app.cochat.ai/papers/10.1111/j.1463-1326.2009.01124.x
The paper
Rosenstock, J., Rendell, M. S., Gross, J. L., Fleck, P. R., Wilson, C. A., & Mekki, Q. (2009). Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA 1c without causing weight gain or increased hypoglycaemia. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2009.01124.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.